FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

	Filed pursua or Se	ant to Section ection 30(h) of	16(a) of the Securities Exc f the Investment Company	hang Act o	e Act of 1 f 1940	934				
Requiri		of Event g Statement Day/Year)	3. Issuer Name and Ticker or Trading Symbol Xilio Therapeutics, Inc. [XLO]							
(Last) (First) (Middle) 300 TECHNOLOGY SQUARE, 8T	_		4. Relationship of Repor Issuer (Check all applicable)	erson(s) to		5. If Amendment, Date of Original Filed (Month/Day/Year)				
FLOOR	_		Director Officer (give title below)	X	Other (s			eck Applicable	nt/Group Filing Line) by One Reporting	
(Street) CAMBRIDGE MA 02139							X	Person Form filed to Reporting F	by More than One Person	
(City) (State) (Zip)										
	Table I - No	on-Deriva	tive Securities Bene	efici	ally Ow	/ned				
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Inst 4)	tr.	3. Owne Form: D (D) or In (I) (Instr.	Direct Owner		ature of Indirect Beneficial nership (Instr. 5)			
Common Stock			26,315		I	See f		footnote ⁽¹⁾		
(e			re Securities Benefic ants, options, conve)			
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)			4. Conve or Exe Price o	rsion (5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr.	
	Date Exercisable	Expiration Date	Title	Nui	ount or mber of ares	Deriva Securi	tive	ive or Indirect 5)		
Series A1 Preferred Stock	(2)	(2)	Common Stock	1,3	72,998	(2))	I	See footnote ⁽¹⁾	
Series B Preferred Stock	(3)	(3)	Common Stock	62	24,089	(3))	I	See footnote ⁽¹⁾	
Series C Preferred Stock	(4)	(4)	Common Stock	54	18,442	(4)	I	See footnote ⁽⁵⁾	
300 TECHNOLOGY SQUARE, 8T (Street) CAMBRIDGE MA	2139 Zip)									
CAMBRIDGE MA (City) (State) (1. Name and Address of Reporting Person	Zip)									

(Middle)

02139

(Zip)

(First)

(State)

400 TECHNOLOGY SQUARE

10TH FLOOR

CAMBRIDGE MA

(Street)

(City)

Name and Address of Reporting Person* Atlas Venture Associates XI, LLC							
(Last) 400 TECHNOL 10TH FLOOR	(First) OGY SQUARE	(Middle)					
(Street) CAMBRIDGE	MA	02139					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* Atlas Venture Opportunity Fund I, L.P.							
(Last) 400 TECHNOL	(First) OGY SQUARE,	(Middle) 10TH FLOOR					
(Street) CAMBRIDGE	MA	02139					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* <u>Atlas Venture Associates Opportunity I,</u> <u>L.P.</u>							
(Last) 400 TECHNOL 10TH FLOOR	(First) OGY SQUARE	(Middle)					
(Street) CAMBRIDGE	MA	02139					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* Atlas Venture Associates Opportunity I, LLC							
(Last) 400 TECHNOL 10TH FLOOR	(First) OGY SQUARE	(Middle)					
(Street) CAMBRIDGE	MA	02139					

Explanation of Responses:

(State)

(Zip)

- 1. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
- 2. The Series A1 Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- 3. The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- 4. The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- 5. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

By: Atlas Venture
Associates XI, LLC, its
general partner, By:
Ommer Chohan, Chief
Financial Officer, /s/
Ommer Chohan

/s/ Atlas Venture Associates XI, LP, By:

Atlas Venture Associates

XI, LLC, it's general

<u>partner, By: Ommer</u> <u>Chohan, Chief Financial</u>

Officer, /s/ Ommer

Chohan

/s/ Atlas Venture

Associates XI, LLC, By:

Ommer Chohan, Chief 10/21/2021

10/21/2021

Financial Officer, /s/ Ommer Chohan

/s/ Atlas Venture

Opportunity Fund I, L.P.,

By: Atlas Venture

Associates Opportunity I,

L.P., its general partner,

By: Atlas Venture 10/21/2021

Associates Opportunity I, LLC, its general partner, By: Ommer Chohan, Chief

Financial Officer, /s/

Ommer Chohan

/s/ Atlas Venture

Associates Opportunity I,

L.P., Atlas Venture

Associates Opportunity I, 10/21/2021

LLC, its general partner,

By: Ommer Chohan, Chief

Financial Officer, /s/

Ommer Chohan

/s/ Atlas Venture

Associates Opportunity I,

LLC, By: Ommer Chohan, 10/21/2021

Chief Financial Officer, /s/

Ommer Chohan

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).